These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31481328)

  • 21. Gene replacement therapy for spinal muscular atrophy unmasking occult hepatitis C in a pediatric patient.
    Lakhotia A; Turek G; Green J; Khan M
    Muscle Nerve; 2022 Jan; 65(1):E2-E3. PubMed ID: 34644404
    [No Abstract]   [Full Text] [Related]  

  • 22. Cellular and molecular approaches to motor neuron therapy in amyotrophic lateral sclerosis and spinal muscular atrophy.
    O'Connor DM; Boulis NM
    Neurosci Lett; 2012 Oct; 527(2):78-84. PubMed ID: 22579818
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating neonatal spinal muscular atrophy: A 21st century success story?
    Tizzano EF
    Early Hum Dev; 2019 Nov; 138():104851. PubMed ID: 31604576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy.
    Pacione M; Siskind CE; Day JW; Tabor HK
    J Neuromuscul Dis; 2019; 6(1):119-131. PubMed ID: 30594933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inpatient rehabilitation admission for a patient with spinal muscular atrophy status post gene therapy.
    Omura JC; Freeman CL; Perlman SJ; Fuentes MM
    PM R; 2023 Oct; 15(10):1361-1362. PubMed ID: 36655390
    [No Abstract]   [Full Text] [Related]  

  • 26. Spinal Muscular Atrophy and Common Therapeutic Advances.
    Bozorg Qomi S; Asghari A; Salmaninejad A; Mojarrad M
    Fetal Pediatr Pathol; 2019 Jun; 38(3):226-238. PubMed ID: 31060440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic strategies for the treatment of spinal muscular atrophy.
    Cherry JJ; Androphy EJ
    Future Med Chem; 2012 Sep; 4(13):1733-50. PubMed ID: 22924510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spinal muscular atrophy: diagnosis and management in a new therapeutic era.
    Arnold WD; Kassar D; Kissel JT
    Muscle Nerve; 2015 Feb; 51(2):157-67. PubMed ID: 25346245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raise the Roof: Boosting the Efficacy of a Spinal Muscular Atrophy Therapy.
    Kramer NJ; Gitler AD
    Neuron; 2017 Jan; 93(1):3-5. PubMed ID: 28056344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis and New Treatment Avenues in Spinal Muscular Atrophy.
    Pechmann A; Kirschner J
    Neuropediatrics; 2017 Aug; 48(4):273-281. PubMed ID: 28571100
    [No Abstract]   [Full Text] [Related]  

  • 31. Gene Therapy Briefs.
    Hum Gene Ther Clin Dev; 2019 Jun; 30(2):43-46. PubMed ID: 31215808
    [No Abstract]   [Full Text] [Related]  

  • 32. Nusinersen in the Treatment of Spinal Muscular Atrophy.
    Goodkey K; Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene Therapy Briefs.
    Philippidis A
    Hum Gene Ther Clin Dev; 2019 Dec; 30(4):149-151. PubMed ID: 31855473
    [No Abstract]   [Full Text] [Related]  

  • 34. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy.
    Valori CF; Ning K; Wyles M; Mead RJ; Grierson AJ; Shaw PJ; Azzouz M
    Sci Transl Med; 2010 Jun; 2(35):35ra42. PubMed ID: 20538619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current research on SMN protein and treatment strategies for spinal muscular atrophy.
    Humphrey E; Fuller HR; Morris GE
    Neuromuscul Disord; 2012 Feb; 22(2):193-7. PubMed ID: 21820901
    [No Abstract]   [Full Text] [Related]  

  • 36. Development of gene therapies-lessons from nusinersen.
    Xu L; Irony I; Bryan WW; Dunn B
    Gene Ther; 2017 Sep; 24(9):527-528. PubMed ID: 28737743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomisation versus prioritisation in a managed access programme: Lessons from spinal muscular atrophy.
    Servais L; Kirschner J; Muntoni F
    Neuromuscul Disord; 2020 Apr; 30(4):267-269. PubMed ID: 32360403
    [No Abstract]   [Full Text] [Related]  

  • 38. Sense in antisense therapy for spinal muscular atrophy.
    MacKenzie A
    N Engl J Med; 2012 Feb; 366(8):761-3. PubMed ID: 22356331
    [No Abstract]   [Full Text] [Related]  

  • 39. Moving towards treatments for spinal muscular atrophy: hopes and limits.
    Wirth B; Barkats M; Martinat C; Sendtner M; Gillingwater TH
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):353-6. PubMed ID: 25920617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent 'value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective.
    Connock M; Andronis L; Auguste P; Dussart C; Armoiry X
    Expert Opin Biol Ther; 2020 Jul; 20(7):823-827. PubMed ID: 32434404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.